FDA Authorizes At-Home Initiation of Alzheimer's Drug Leqembi

The FDA has approved a new starting dosage for the Alzheimer's treatment Leqembi, enabling patients to begin subcutaneous administration at home. This marks a significant shift from the previous requirement for intravenous initiation, offering greater convenience and accessibility for individuals managing Alzheimer's disease. The change could improve patient adherence and quality of life.